" class="no-js "lang="en-US"> 3Spine - Medtech Alert
Tuesday, March 21, 2023

Breaking News

Axel Hoos, MD, PhD, Joins NextPoint Therapeutics Board of Directors Coya Therapeutics Announces Positive Results from a Proof-of-Concept Academic Clinical Study for COYA 302 in Amyotrophic Lateral Sclerosis (ALS) BeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint in New Jersey Mindset Health Raises $12M to Expand Digital Hypnotherapy Apps & Scale Distribution GeneDx Announces Progress on GUARDIAN Study and Promise of Early Genomic Testing to End Rare Disease “Diagnostic Odyssey” Dupixent® (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis Gamida Cell Announces Changes to Board of Directors Newron Reports Topline Results From All Patients in Study Evaluating Evenamide as Add-on Therapy for Treatment-Resistant Schizophrenia Ascidian Therapeutics Appoints Jay A. Barth, M.D., as Chief Medical Officer TFS HealthScience Expands Operations into Israel, With Focus on Continuous, Rapid International Expansion
3Spine | Pharmtech Focus

3Spine

About 3Spine

3Spine
3Spine is a privately-held medical device company offering MOTUS and the BalancedBack Total Joint Replacement procedure, an alternative to spinal fusion for patients suffering from leg and back pain.

Related Story

Clinical Trials

 3Spine

3Spine, Inc. Completes First US Surgeries

June 30 2022

3Spine, Inc., a medical device company developing total joint replacement for the lumbar spine, today […]